BRCA1 and neoplasm: There was a general decrease in proliferation in tumors treated with cisplatin or the combination of cisplatin and olaparib compared to vehicle in both Brca1-deficient tumor models, but not in the Brca1-wild type model (Fig. 4B), even though Brca1-wild type model was treated for a longer time (3 weeks).